Half-year Financial Report

AI SummaryClose X

Fusion Antibodies plc reported revenues of £0.84 million for the six months ended 30 September 2025, a decrease from £1.2 million in the prior year period, though an increase from the preceding six months. The company saw a significant rise in R&D expenditure to £350,000, contributing to a reduced loss of £0.51 million, a 32% improvement from £0.76 million in H1 FY2025. The cash position stood at £0.25 million as of 30 September 2025, with an additional £543,000 owed by debtors. Key operational developments include a US patent grant for its OptiMAL® technology and positive validation results with the National Cancer Institute, alongside new contracts for cell line development and humanisation projects with major pharmaceutical companies, with a potential pipeline value for OptiMAL® estimated at £1 million.

Disclaimer*

UK 100

Latest directors dealings